Showing results (1-10 of 153) with videos related to
Sort By:
Pageof 16
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|March 23, 2020
CAR-T treatment for hematological malignanciesShebli Atrash, Kulsum Bano, Bradley Harrison, et al.Journal of Global Oncology|September 23, 2018
Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and Waldenström MacroglobulinemiaShebli Atrash, Qing Zhang, Xenofon Papanikolaou, et al.The American Journal of Case Reports|April 10, 2013
Unilateral conjunctival AL kappa amyloidosis with trace evidence of systemic amyloidosisAl-Ola Abdallah, Christopher Westfall, Harry Brown, et al.Current Oncology (Toronto, Ont.)|September 26, 2025
CAR-T Access Disparities for Multiple Myeloma in the Midwest: A Social Determinants of Health PerspectiveMichael Weise, Shebli Atrash, Briha Ansari, et al.Cancers|June 10, 2023
Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed TherapyShebli Atrash, Aytaj Mammadzadeh, Fulei Peng, et al.Clinical Lymphoma, Myeloma & Leukemia|October 14, 2020
Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple MyelomaAl-Ola Abdallah, Ghulam Rehman Mohyuddin, Zahra Mahmoudjafari, et al.Journal of Hematology|March 10, 2023
Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and DexamethasoneOmar Alkharabsheh, Polina Bellman, Zahra Mahmoudjafari, et al.Cancers|October 14, 2023
Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab-Naïve Relapsed Multiple MyelomaAimaz Afrough, Shebli Atrash, Barry Paul, et al.Ejhaem|July 18, 2022
Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary diseaseAl-Ola Abdallah, Ghulam Rehman Mohyuddin, Nausheen Ahmed, et al.Cancers|January 10, 2026
Outcomes of pPCL Diagnosed Using the IMWG 2021 Consensus Definition: A Retrospective Multicenter AnalysisPriyanka Venkatesh, Razan Mansour, Yara Shatnawi, et al.Pageof 16